Clinical Trial Update: Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates the PET tracer [18F]RO6958948 for imaging tau burden in Alzheimer's disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• 18F-RO6958948

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED